Human Polyclonal MDM2 Ab
- Known as:
- Human Polyclonal MDM2 Antibody
- Catalog number:
- a0345
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- ABclonal
- Gene target:
- Human Polyclonal MDM2
Related genes to: Human Polyclonal MDM2 Ab
- Gene:
- MDM2 NIH gene
- Name:
- MDM2 proto-oncogene
- Previous symbol:
- -
- Synonyms:
- HDM2, MGC5370
- Chromosome:
- 12q15
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-10
- Date modifiied:
- 2017-12-01
Related products to: Human Polyclonal MDM2 Ab
Related articles to: Human Polyclonal MDM2 Ab
- Targeting the ubiquitin-proteasome system has emerged as a powerful therapeutic strategy in oncology, particularly through modulation of deubiquitinating enzymes that regulate the stability of oncogenic proteins. Among these, ubiquitin-specific protease 7 (USP7) has garnered considerable attention due to its ability to deubiquitinate and stabilize multiple cancer-relevant substrates, including MDM2, FOXP3, N-Myc, and PTEN. By controlling protein turnover and subcellular localization of substrates, USP7 contributes to tumor progression across diverse types of cancer, positioning it as an attractive therapeutic target. Here, we report the identification of novel small-molecule USP7 inhibitors from a high-throughput screening campaign employing the fluorogenic ubiquitin-rhodamine enzymatic assay. Screening of 2446 compounds led to the identification of five hit compounds with measurable inhibitory activity against recombinant USP7 in vitro. These hits were further evaluated for antiproliferative activity across a panel of human and murine cancer cell lines with distinct molecular backgrounds. Among the identified hits, YM155 displayed the highest activity across all cancer types tested, exhibiting nanomolar IC values in the proliferation assays. Importantly, YM155 demonstrated significant tumor growth inhibition in lung and breast cancer mouse models, supporting its in vivo activity and pharmacological tractability in clinically relevant settings. Together, these findings expand the chemical space of USP7 inhibitors and identify YM155 as a hit for further optimization and mechanistic investigation toward USP7-targeted anticancer therapeutics. - Source: PubMed
Publication date: 2026/07/28
Oliveira Rita IFranco CaioMano MiguelHabboub RahafEisenbarth DavidLeal Ana SSalvador Jorge A R - Chondrosarcomas are malignant cartilage-forming bone tumors with limited therapeutic options, as surgical resection remains the only curative treatment, while chemo- and radiotherapy show limited efficacy due to intrinsic resistance mechanisms. Dysregulation of the Hippo signaling pathway been associated with tumor progression and therapy resistance and has emerged as a promising experimental target across several cancer entities. However, its relevance in chondrosarcoma remains unclear, particularly with regard to potential radiosensitizing effects. - Source: PubMed
Publication date: 2026/07/13
Lohberger BirgitGlänzer DietmarKaltenegger HeikeKolb Dagmar - Lactation traits are important indicators for evaluating the production performance of dairy cows and the economic efficiency of dairy production. Identifying potential regulatory genes is essential for elucidating the molecular mechanisms underlying lactation and facilitating molecular breeding. This study aimed to identify candidate genes and regulatory pathways potentially associated with lactation traits in dairy cows by integrating transcriptome expression profiles of primary bovine mammary epithelial cells (BMECs) from eight Holstein cows with lactation phenotypic data. A gene co-expression network was constructed using weighted gene co-expression network analysis (WGCNA). Co-expression modules associated with lactation traits were identified, and candidate genes were further screened by integrating gene significance, module membership, functional enrichment analysis, random forest analysis, gene-phenotype association analysis, single-gene gene set enrichment analysis (GSEA), ROC curve analysis, and tissue expression profiling. Four co-expression modules, namely MEdarkturquoise, MEsteelblue, MEbrown, and MEskyblue3, were significantly associated with lactation traits ( < 0.05). Genes in these modules were mainly enriched in biological processes and pathways related to ribosome biogenesis, protein translation, the cell cycle, oxidative phosphorylation, and the PI3K-Akt signaling pathway, which may be involved in lactation regulation. Through multi-strategy cross-screening, four candidate genes were ultimately identified. 2 was associated with daily milk yield (DYM), A with total milk solids (TMS), and 25 and 2 with milk fat percentage (MFP) and fat-to-protein percentage ratio (FPP). Reverse transcription quantitative real-time PCR (RT-qPCR) validation showed that 2 and were relatively highly expressed in mammary tissue, suggesting that they may be involved in lactation-related biological processes in dairy cows. These findings provide potential candidate regulators and theoretical support for further studies on the molecular mechanisms of lactation traits; however, their functional roles require further validation through in vitro and in vivo experiments. - Source: PubMed
Publication date: 2026/07/16
Mu TongQiao ZhixuanHu HonghongMa YunJiang ZiyanHuang YuxinSun Zhihong - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and one of the most common hematological neoplasia. Entropy is a statistical measure of randomness that characterizes the texture of an input image and measures tissue complexity. Image processing and computer vision analysis were performed on a series of 114 diagnostic DLBCL cases and 44 reactive lymphoid tissues stained with hematoxylin and eosin (H&E). Histological entropy was measured to differentiate between reactive lymphoid tissue and DLBCL and predict clinical evolution. At protein level, immunohistochemistry analyzed Ki67, LMO2, MYC, MDM2, CDK6, E2F1, BCL2, CASP8, MYOB, TP53, cPARP, cCASP3, ISY1, TNFAIP8, CSF1R, CD163, PD-L1 and IL-10 markers. Gene expression analysis using the NanoString nCounter PanCancer Immune Profiling Panel was performed in 29 cases. In comparison with reactive lymphoid tissue, DLBCL was characterized by lower entropy (7.32 ± 0.16 vs. 6.82 ± 0.44, respectively; < 0.001). Within the DLBCL diagnostic category, higher entropy was associated with poor overall survival and death events within the first 2 years (hazard-risk = 2.4, = 0.004) and lower entropy with a moderate and more favorable outcome (hazard-risk = 0.4, = 0.004). High entropy was also correlated with ECOG performance status ≥ 2, lower protein expression of apoptosis markers of cPARP and cCASP3, and upregulation of specific immuno-oncology genes such as STAT3, BTK, CASP8, CD47, VCAM1, and MYD88. The prognostic value of entropy was independent of the international prognostic index (IPI), Epstein-Barr virus (EBER), and cell of origin (Hans). The histological evaluation of entropy is useful for the differential diagnosis of reactive lymphoid tissue and DLBCL and is a predictive factor of DLBCL prognosis. - Source: PubMed
Publication date: 2026/07/15
Carreras JoaquimKikuti Yara YukieNagase ShunsukeRoncador GiovannaIkoma HarukaIto AtsushiOrita MakotoTomita SakuraTanigaki YukiUeno AkihisaKondo YusukeNakamura NaoyaMasugi Yohei - The development of multi-targeted therapeutic agents is increasingly recognized as essential for treating multifactorial diseases. Butyrolactone I and butyrolactone III, γ-butyrolactone derivatives isolated from the marine fungus , represent structurally related natural products with largely unexplored polypharmacological potential. This study employed a comprehensive in silico approach combining ADMET profiling, quantum chemical calculations, molecular docking, and molecular dynamics simulations to evaluate their therapeutic potential across multiple pharmacological targets. Physicochemical analysis revealed favorable drug-like properties for both compounds, with complete compliance with Lipinski's Rule of Five, high predicted gastrointestinal absorption (>80%), and acceptable toxicity profiles (toxicity class 4, LD = 2000 mg/kg). Neither compound showed hepatotoxic, neurotoxic, cardiotoxic, carcinogenic, or mutagenic liabilities. Frontier molecular orbital analysis (DFT/B3LYP/6-31G(d,p)) revealed comparable HOMO energies (-6.054 and -6.059 eV), with butyrolactone III exhibiting enhanced kinetic stability based on a larger HOMO-LUMO gap (4.662 eV vs. 4.443 eV) and higher chemical hardness (η = 2.331 eV vs. 2.222 eV). Molecular docking against four therapeutic targets revealed target-selective binding profiles: butyrolactone III demonstrated binding affinity toward acetylcholinesterase exceeding donepezil (-9.0 vs. -8.3 kcal/mol), while butyrolactone I exhibited MDM2 binding affinity slightly exceeding nutlin-3a (-7.8 kcal/mol). Both compounds showed moderate interactions with COX-2 and topoisomerase IV. Molecular dynamics simulations validated the stability of AChE complexes (RMSD < 2.0 Å) and the MDM2-butyrolactone I complex (RMSD: 0.69 ± 0.09 Å), while the MDM2-butyrolactone III complex exhibited significant instability (RMSD up to 3.55 Å), highlighting the critical role of the prenyl group in MDM2 recognition. These findings, consistent with, though not a direct experimental validation of, previously published in vitro data, support the evaluation of butyrolactone III as a scaffold for neuroprotective agents and butyrolactone I as a p53 pathway modulator for cancer therapy, illustrating the potential value of fungal metabolites in multi-target drug discovery and the role of integrated computational approaches in prioritizing candidates for subsequent experimental testing. - Source: PubMed
Publication date: 2026/07/10
Kowalczyk TomaszMerecz-Sadowska AnnaKonuklugil BelmaUras İbrahim SeydaZajdel RadosławRijo PatriciaSitarek Przemysław